August 19, 2021

The company holds 29 issued patents worldwide, covering key structural innovations in Left Atrial Appendage Occlusion (LAAO) technology, including implant design and conformability features.

Cloud-based solution monitors temperature and humidity of refrigerators and regulated rooms with real-time alerts to ensure the safety and effectiveness of medications and biologicals

Partnership further validates Ethris’ novel technology platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity of mRNA.

CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent.

This designation represents a key milestone toward future reimbursement and broader clinical adoption.